Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic evaluation of anti-factor Xa variability after therapeutic nadroparin in critically ill adults
NL-OMON20466Recruiting
- Sponsor
- Martini Ziekenhuis
- Start
- Jul 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of nadroparin in venous thromboembolism (VTE) and Atrial fibrillation (AFib), sponsored by Martini Ziekenhuis. Primary endpoint: Incidence of inadequate estimated peak anti-factor-Xa levels. Started Jul 2020; status: recruiting.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON20466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20466.